Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2839590 | Clínica e Investigación en Arteriosclerosis | 2013 | 6 Pages |
Abstract
Statins are the current basis of lipid-lowering therapy, despite which may have limitations on efficacy and safety. In high risk patients who do not achieve current lipid goals, in those intolerant to statins or those with atherogenic dyslipidemia, it is possible combine two or more lipid lowering drugs, including statins, ezetimibe, bile acid sequestrants, fibrates, niacin and prescription omega-3 fatty acids. However, for most of these combination therapies pivotal data on clinical outcomes are still lacking.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Physiology
Authors
Ovidio Muñiz Grijalvo, Jose Villar Ortiz,